https://e-journal.unair.ac.id/FMI/issue/feed Folia Medica Indonesiana 2022-09-21T09:41:47+00:00 Prof. Dr. Kuntaman, dr., MS., SpMK(K). fmi@journal.unair.ac.id Open Journal Systems <p align="justify"><strong>Folia Medica Indonesiana </strong>is the medical journal of Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. The first volume of the journal was released in 1964 under the title of "Berita Research Kedokteran Surabaja". At the end of the 1960s, the journal changed its name to "Madjalah Kedokteran Surabaja", which then in the 1970s the spelling was adjusted to become "Majalah Kedokteran Surabaya", and in the mid of 1997 the journal again changed its name into the current "Folia Medica Indonesiana". <strong>Folia Medica Indonesiana</strong> publishes articles in whole aspects of medical and health sciences produced from basic sciences, clinical, and community or public health research.<br /><br /><strong>Folia Medica Indonesiana</strong> is published four times a year in March, June, September, and December. Each issue publishes fifteen articles or sixty articles in each calendar year. The content of the journal can be accessed openly, making the articles freely available to endorse the global exchange of knowledge. Folia Medica Indonesiana has been accredited by the Ministry of Research, Technology, and Higher Education, the Republic of Indonesia as an academic journal <a href="https://drive.google.com/file/d/113iuLAK6QrsMkQysnIFzeq6oSo1wBOxF/view" target="_blank" rel="noopener">No.158/E/KPT/2021</a> which applies from Vol. 56 No. 4 2020 and is valid until Vol. 61 No. 3 2025. <strong>Folia Medica Indonesiana</strong> has also been indexed in several reputable indexing institutions, such as <a href="https://www.proquest.com/sessionexpired?accountid=31533" target="_blank" rel="noopener">ProQuest</a>, <a href="https://search.crossref.org/?q=Folia+Medica+Indonesiana&amp;from_ui=yes" target="_blank" rel="noopener">Crossref</a>, <a href="https://asean-cites.org/aci_search/journal.html?b3BlbkpvdXJuYWwmaWQ9MTEzMTY" target="_blank" rel="noopener">ASEAN Citation Index</a>, and the <a href="https://doaj.org/toc/2599-056X?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22terms%22%3A%7B%22index.issn.exact%22%3A%5B%222355-8393%22%2C%222599-056X%22%5D%7D%7D%5D%7D%7D%2C%22size%22%3A100%2C%22sort%22%3A%5B%7B%22created_date%22%3A%7B%22order%22%3A%22desc%22%7D%7D%5D%2C%22_source%22%3A%7B%7D%2C%22track_total_hits%22%3Atrue%7D" target="_blank" rel="noopener">Directory of Open Access Journals (DOAJ)</a>.</p> https://e-journal.unair.ac.id/FMI/article/view/39184 Front Matter Vol.58 No.3 September 2022 2022-09-21T09:41:47+00:00 FMI fmi@journal.unair.ac.id <p>front matter</p> 2022-09-05T00:00:00+00:00 Copyright (c) 2022 Folia Medica Indonesiana https://e-journal.unair.ac.id/FMI/article/view/38337 Back Matter Vol.58 No.3 September 2022 2022-08-16T04:47:12+00:00 Folia Medica Indonesiana foliamedica@gmail.com <p>Back Matter Vol.58 No.3 September 2022</p> 2022-09-05T00:00:00+00:00 Copyright (c) 2022 Folia Medica Indonesiana https://e-journal.unair.ac.id/FMI/article/view/37209 Spike-Receptor Binding Domain (SRBD) Antibodies Secretion in COVID-19 Survivors and Non-Survivors Post-Pre-Endemic Vaccination 2022-07-26T04:31:02+00:00 Museyaroh muzayarohfauziah@gmail.com Evy Dyah Woelansari evydiahws@gmail.com Dwi Kriharyani dwi.krihariyani-2018@fk.unair.ac.id <p><strong>Highlights</strong></p> <ol> <li>The research this for determine the presence of immune response post-vaccine</li> <li>The results of this study indicate that there are differences in immune responses, in survivors patients have higher SRBD antibody levels than non-survivors</li> </ol> <p> </p> <p><strong>Abstract :</strong></p> <p>The development of a vaccine for SARS-COV-2 began in mid-2020 with the aim of stimulating an individual's immune response against SARS-CoV-2 infection. The purpose of this study was to determine the levels of post-vaccine SRBD antibody secreted in COVID-19 survivors and non-survivors. Antibodies are considered to play a more important role in evaluating immunity because antibody tests may provide information about a person's immune status against SARS-CoV-2. The study was conducted at Husada Utama Hospital, Surabaya, Indonesia, in April – May 2021. The samples were taken prospectively with a total sample of 60 patients, consisting of 40 non-survivors and 20 survivors of COVID-19 who had received Sinovac vaccine doses 1 and 2. Examination of Sars-CoV-2 SRBD antibody was conducted by using CL series of Mindray device by means of CLIA method. The average level of antibody was assessed in each sample group and the results were subjected to the Mann Whitney test. The mean SRBD antibody level in female patients was 428.24 ± 271.25, while in male patients it was 310.40 ± 113.71 U/mL. The results of the Mann Whitney test revealed a P-Value of 0.09 &gt; 0.05, indicating no difference in post-vaccine SRBD antibody levels between females and males, but there were differences in SRBD antibody levels in COVID-19 survivors and non-survivors with a P-Value of &lt;, i.e. 0.00 &lt; 0.05 There was no difference in post-vaccine SRBD antibody levels between females and males in COVID-19 survivors and non-survivors, but there were differences in post-vaccine antibody levels between COVID-19 survivors and non-survivors.</p> 2022-09-05T00:00:00+00:00 Copyright (c) 2022 Folia Medica Indonesiana https://e-journal.unair.ac.id/FMI/article/view/36332 Back Matter Vol. 58 No. 2 June 2022 2022-06-03T05:14:10+00:00 Back Matter fmi@journal.unair.ac.id <p>&nbsp; &nbsp;</p> 2022-06-05T00:00:00+00:00 Copyright (c) 2022 Folia Medica Indonesiana https://e-journal.unair.ac.id/FMI/article/view/36331 Front Matter Vol. 58 No. 2 June 2022 2022-06-03T05:01:05+00:00 Folia Medica Indonesiana fmi@journal.unair.ac.id <p>&nbsp;&nbsp;</p> 2022-06-05T00:00:00+00:00 Copyright (c) 2022 Folia Medica Indonesiana